Javascript must be enabled to continue!
Comparative study on the effects of filgrastim and pegfilgrastim in the treatment of fever and neutropenia in patients with leukemia in the west of Iran
View through CrossRef
Background: The current research seeks to present a comparative study of the effect of filgrastim and pegfilgrastim in the treatment of fever and neutropenia in leukemia patients.
Materials and Methods: The present study is a blind randomized clinical trial. The study population is comprised of 120 children with acute lymphoblastic leukemia (ALL) who were admitted to the hospital due to mild febrile neutropenia during 2019. Included patients were divided into two groups. Filgrastim (10 micrograms/ kilogram, daily subcutaneously) and pegfilgrastim (100 micrograms per kilogram of a subcutaneous dose) were used for groups, respectively. Fever monitored every 6 hours, and neutrophil count was performed every 48 hours. The questionnaire designed in the study included age, type of drug side effects, number of days of neutropenia, and fever cessation time. Then, the data were analyzed by SPSS software.
Result: Leukemic children with fever and neutropenia (N=120) were included in the study, which was 59 (49.1%) male and 61 (50.9%) female by the mean age of 79±44 months. The mean days of neutropenia correction in the filgrastim and pegfilgrastim groups were 5 and 4 days, respectively, which was not significantly different (p =0.08). There was no correlation between patients’ complications and types of treatments (p>0.05). Muscular pain was the most common complication observed among 4 cases and 1 case following filgrastim and pegfilgrastim administration, respectively. Furthermore, hyperleukocytosis following pegfilgrastim consumption was observed in two cases.
Conclusion: There was no significant correlation between the duration until the cessation of fever and the number of neutropenia days in the two groups receiving pegfilgrastim and filgrastim. Therefore, the fever and neutropenia improve with pegfilgrastim earlier than filgrastim; besides, fewer injections, patient comfort, and less musculoskeletal pain can be observed.
Title: Comparative study on the effects of filgrastim and pegfilgrastim in the treatment of fever and neutropenia in patients with leukemia in the west of Iran
Description:
Background: The current research seeks to present a comparative study of the effect of filgrastim and pegfilgrastim in the treatment of fever and neutropenia in leukemia patients.
Materials and Methods: The present study is a blind randomized clinical trial.
The study population is comprised of 120 children with acute lymphoblastic leukemia (ALL) who were admitted to the hospital due to mild febrile neutropenia during 2019.
Included patients were divided into two groups.
Filgrastim (10 micrograms/ kilogram, daily subcutaneously) and pegfilgrastim (100 micrograms per kilogram of a subcutaneous dose) were used for groups, respectively.
Fever monitored every 6 hours, and neutrophil count was performed every 48 hours.
The questionnaire designed in the study included age, type of drug side effects, number of days of neutropenia, and fever cessation time.
Then, the data were analyzed by SPSS software.
Result: Leukemic children with fever and neutropenia (N=120) were included in the study, which was 59 (49.
1%) male and 61 (50.
9%) female by the mean age of 79±44 months.
The mean days of neutropenia correction in the filgrastim and pegfilgrastim groups were 5 and 4 days, respectively, which was not significantly different (p =0.
08).
There was no correlation between patients’ complications and types of treatments (p>0.
05).
Muscular pain was the most common complication observed among 4 cases and 1 case following filgrastim and pegfilgrastim administration, respectively.
Furthermore, hyperleukocytosis following pegfilgrastim consumption was observed in two cases.
Conclusion: There was no significant correlation between the duration until the cessation of fever and the number of neutropenia days in the two groups receiving pegfilgrastim and filgrastim.
Therefore, the fever and neutropenia improve with pegfilgrastim earlier than filgrastim; besides, fewer injections, patient comfort, and less musculoskeletal pain can be observed.
Related Results
Comparison of Infection-Related Hospitalization Risk and Associated Costs among Patients Receiving Sargramostim (Leukine®), Filgrastim (Neupogen®), and Pegfilgrastim (Neulasta®) for Chemotherapy-Induced Neutropenia
Comparison of Infection-Related Hospitalization Risk and Associated Costs among Patients Receiving Sargramostim (Leukine®), Filgrastim (Neupogen®), and Pegfilgrastim (Neulasta®) for Chemotherapy-Induced Neutropenia
Abstract
Background: Neutropenia is a main side effect of cancer treatment and leads to increased risk of serious infections. Myeloid growth factors, including the g...
To analyze efficacy and safety of pegfilgrastim versus filgrastim in patients with breast cancer
To analyze efficacy and safety of pegfilgrastim versus filgrastim in patients with breast cancer
e20587 Background: We evaluated the safety and efficacy of a single fixed 6 mg dose of pegfilgrastim (a pegylated version of filgrastim) per cycle of chemotherapy, compared with d...
Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy‐Induced neutropenia
Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy‐Induced neutropenia
AbstractBACKGROUND:Sargramostim is a granulocyte‐macrophage–colony‐stimulating factor (GM‐CSF). Unlike filgrastim and pegfilgrastim, which are granulocyte–colony‐stimulating factor...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Use Of Biosimilar G-CSF Compared With Lenograstim In Autologous Haematopoietic Stem Cell Transplant and In Sibling Allogeneic Transplant
Use Of Biosimilar G-CSF Compared With Lenograstim In Autologous Haematopoietic Stem Cell Transplant and In Sibling Allogeneic Transplant
Abstract
Introduction
Biosimilar filgrastim is now widely used for haematopoietic stem cell mobilisation in Europe. Previous stu...
Peg-Filgrastim after Autologous Peripheral Blood Stem Cell Transplantation in Hematological Malignancies.
Peg-Filgrastim after Autologous Peripheral Blood Stem Cell Transplantation in Hematological Malignancies.
Abstract
ASCO guidelines recommend the use of granulocyte-colony stimulating factors (G-CSF) as adjuvant agents after autologous peripheral blood stem cell transplan...
A Single-Center Large Cohort of Chronic Neutropenia Patients and a Model for Estimation of Congenital Neutropenias
A Single-Center Large Cohort of Chronic Neutropenia Patients and a Model for Estimation of Congenital Neutropenias
Chronic neutropenia (CrN) is defined as neutropenia lasting longer than 3 months and has various underlying etiologies, including congenital neutropenia (CN). We aimed to determine...
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...

